Efficacy and safety of gemcitabine/nab-paclitaxel combined with anlotinib and PD-1 inhibitors as a first-line treatment for advanced pancreatic cancer
-
Published:2024-09
Issue:
Volume:139
Page:112635
-
ISSN:1567-5769
-
Container-title:International Immunopharmacology
-
language:en
-
Short-container-title:International Immunopharmacology
Author:
Liu Haonan,
Pan Di,
Yao Zhiyuan,
Wang Hongmei,
Li Yuqi,
Qin Xiaobing,
Qu Pengfei,
Tang Juanjuan,
Han ZhengxiangORCID